ISPC Is The New LGVN. Will It Also Hit $30?

They say to never trust an anonymous blogger on the internet. And I am an anonymous blogger. I have my reasons for remaining anonymous, and those reasons don't matter. Can you really trust articles on Bloomberg or Wall Street Journal any more than an anonymous opinion? All I ask is to debate the content of my message. Not who I am or my motivations. If you agree with what I say and think that it's in-depth, quality and truthful work, then make sure to share this on every retail channel available to you. Reddit, Discord, Stocktwits, Twitter, Telegram, Whatsapp, Tiktok and wherever else. I have just added a follow option at the top left for those who want to be notified when more blogs come out. 

Longeveron Inc. (LGVN) has been a massively hot stock since the company received good news from the FDA last week. The stock closed at $2.92 on November 17, the day before the news shot it up as high as over $30 in post-market trading on Monday and pre-market trading this morning. iSpecimen Inc. (ISPC) is LGVN's twin as it shot up after announcing that it was Selected by U.S. Government and Private Researchers to Supply Critical Human Biospecimens for Advanced Phase of COVID-19 Research. 

ISPC can be considered LGVN's twin because both of them were recent IPOs in the health care space over the past year, plus they have very similar floats:

ISPC has a smaller market cap, and I think it's a better deal right now because its news relates to actual revenue generating activities with contracts from government and private researchers for the fight against COVID-19.

But the real opportunity here is how each stock trades and how that trading pattern on LGVN before it broke out to $30 matches ISPC's forming pattern very closely. 

Day one:

On November 18, LGVN opened at $3.72, hit a high of $8.90 but actually performed quite weak in afternoon trading and closed at $6.87, up 135% on the day. However, in the after hours market, the stock shot up to over $10.

On November 22, ISPC opened at $11.39, hit a high of $12.77 but also performed weak in the afternoon, dropping to $8.88 and closing up 80% on the day. However, in after hours trading, it shot up over $15.

On both of those days, shorts, trolls and other people who think they are smarter than they really are talked non-stop about equity offerings. Neither stock announced an equity offering and the results show in the stock price the next day. 

Day two:

On November 19, LGVN opened at $11.81, a 72% spike from the previous day's close. It hit a high of $14.75 but ended up selling off the rest of the day to close at $10.03

Today, ISPC opened at $16.84, a 90% spike from the previous day's close. It hit a high of $18.50 but pulled back as low as $11.20 before rebounding to close at $13.19. 

Day three: 

On November 22, LGVN opened down at $8.71, but saw continuous buying throughout the day to close at $28.20. 

Is this the fate of ISPC tomorrow? So far they have been trading very similarly. They both have similar floats, are recent healthcare IPOs and have had great news recently. ISPC has the advantage of generating operating revenues right now while LGVN's revenues have been from grants and clinical trials. ISPC's current news creates expectations that it will have good revenue growth right now, while LGVN's revenues will come in the future assuming successful clinical trials and FDA approval of a marketable drug. 

Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more